The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
Immunotherapy Gastroesophageal Junction
DRUG: Tislelizumab|DRUG: Anlotinib|DRUG: Oxaliplatin|DRUG: Tegafur
Pathological complete response, Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery
Major pathological response, Total/moderate tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery|Objective Response Rate (ORR), Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor, At the end of Cycle 3 (each cycle is 21 days)
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer